<DOC>
	<DOCNO>NCT00025324</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy , surgery , radiation therapy , bone marrow peripheral stem cell transplantation treat patient primary CNS germ cell tumor .</brief_summary>
	<brief_title>Chemotherapy , Surgery , Radiation Therapy Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Primary CNS Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine two-year event-free survival patient primary CNS germ cell tumor treat carboplatin , etoposide , cyclophosphamide , filgrastim ( G-CSF ) without radiotherapy and/or high-dose chemotherapy autologous bone marrow peripheral blood stem cell transplantation . - Determine prognostic significance slow-responding tumor marker normalization patient treat regimen . - Determine prognostic significance syncytiotrophoblastic giant cell component cerebrospinal fluid beta-human chorionic gonadotropin elevation patient treat regimen . - Assess early late endocrinologic , neuropsychometric , quality life sequela patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord risk status ( low v intermediate high ) . Regimen A ( Low-risk patient ) - Chemotherapy : Patients receive carboplatin IV 4 hour etoposide IV 2 hour day 1-2 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 3 continue blood count recover ( course 1 ) . Patients also receive cyclophosphamide IV 1 hour etoposide IV 2 hour day 22 23 G-CSF SC daily begin day 24 continue blood count recover ( course 2 ) . - Patients complete response ( CR ) initial chemotherapy receive 2 additional course chemotherapy proceed observational phase . Patients partial response ( PR ) initial chemotherapy receive 2 additional course chemotherapy . - Patients CR additional chemotherapy receive another 2 additional course chemotherapy proceed observational phase . Patients PR additional chemotherapy undergo biopsy and/or resection residual tumor . - Patients evidence malignant germ cell tumor ( GCT ) resection undergo radiotherapy . Patients evidence malignant GCT resection scar , fibrosis , mature teratoma receive 2 additional course chemotherapy proceed observational phase . Patients evidence malignant GCT resection immature teratoma receive carboplatin IV 4 hour , cyclophosphamide IV 1 hour , etoposide IV 2 hour day 1-2 22-23 . Patients underwent complete resection residual tumor proceed observational phase . Patients underwent biopsy incomplete resection residual tumor undergo radiotherapy . Regimen B ( Intermediate high-risk patient ) - Patients receive carboplatin IV 4 hour , cyclophosphamide IV 1 hour , etoposide IV 2 hour day 0-1 . Patients also receive G-CSF SC daily begin day 2 continue blood count recover . Treatment repeat every 21 day total 2 course . Patients undergo bone marrow peripheral blood stem cell harvest prior second course chemotherapy . - Patients rapid CR 2 initial course chemotherapy receive additional 2 course chemotherapy proceed observational phase . Patients PR slow response 2 initial course chemotherapy receive 2 additional course chemotherapy . Patients CR course 3 4 receive 2 course chemotherapy proceed observational phase . Patients PR course 3 4 undergo biopsy and/or resection residual tumor . - Patients evidence malignant GCT resection scar , fibrosis , mature teratoma receive carboplatin IV 4 hour etoposide IV 2 hour day 1 2 cyclophosphamide IV 1 hour etoposide IV 2 hour day 22 23 proceed observational phase . Patients teratoma resection receive additional treatment regimen A . Patients evidence pure germinoma resection undergo radiotherapy . - Patients evidence malignant GCT resection undergo high-dose chemotherapy ( HDCx ) bone marrow peripheral blood stem cell support ( PBSCS ) comprise thiotepa IV 3 hour etoposide IV 1 hour day -8 -6 ; carboplatin IV 4 hour day -5 -3 ; reinfusion autologous bone marrow peripheral blood stem cell day 0 ; G-CSF SC IV every 12 hour begin day 1 continue blood count recover . Patients undergo radiotherapy . Quality life assess bone marrow PBSCS every 2 year thereafter . Patients follow day 42 , 3 month , every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 80 patient ( 40 per stratum ) accrue study within 4 year .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose primary CNS germ cell tumor OR Serum cerebrospinal fluid ( CSF ) elevation alphafetoprotein ( AFP ) betahuman chorionic gonadotropin ( betaHCG ) great 50 ng/mL Lowrisk disease : Histologically proven pure germinoma Localized , nonmetastatic disease Normal CSF Normal serum tumor marker Intermediaterisk disease : Histologically proven germinoma BetaHCGpositive syncytiotrophoblastic giant cell component AND/OR CSF elevation betaHCG le 50 ng/mL Highrisk disease : Histologically proven choriocarcinoma , endodermal sinus tumor , embryonal carcinoma Elevated serum and/or CSF AFP OR Elevated serum betaHCG OR Elevated CSF betaHCG great 50 ng/mL OR Disseminated disease MRI and/or CSF cytology PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL Indirect hyperbilirubinemia due Gilbert 's syndrome allow AST ALT less 5 time upper limit normal Renal : Creatinine clearance great 60 mL/min Cardiovascular : Cardiac function normal echocardiogram No myocardial infarction ischemia patient 30 year Fractional shortening great 30 % Other : No unacceptable morbidity organ system outside CNS Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent corticosteroid administer solely antiemesis study chemotherapy Radiotherapy : No prior cranial radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
</DOC>